Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II-III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysis.

Saved in:
Bibliographic Details
Title: Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II-III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysis.
Authors: Frei AL; Department of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; Life Science Zurich Graduate School, PhD Program in Biomedicine, University of Zurich, Zurich, Switzerland., McGuigan A; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Sinha RRAK; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Jabbar F; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Gneo L; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Tomasevic T; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Harkin A; Cancer Research UK Glasgow Clinical Trials Unit, University of Glasgow, Glasgow, UK., Iveson T; Southampton University, Southampton, UK., Saunders MP; The Christie NHS Foundation Trust, Manchester, UK., Oien KA; School of Cancer Sciences, University of Glasgow, Glasgow, UK; Glasgow Tissue Research Facility, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, UK., Maka N; Glasgow Tissue Research Facility, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, UK., Pezzella F; Nuffield Division of Clinical and Laboratory Sciences, University of Oxford, Oxford, UK., Campo L; Department of Oncology, University of Oxford, Oxford, UK., Browne M; Department of Oncology, University of Oxford, Oxford, UK., Glaire M; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Kildal W; Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway., Danielsen HE; Nuffield Division of Clinical and Laboratory Sciences, University of Oxford, Oxford, UK; Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway., Hay J; Glasgow Tissue Research Facility, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, UK., Edwards J; School of Cancer Sciences, University of Glasgow, Glasgow, UK., Sansom O; School of Cancer Sciences, University of Glasgow, Glasgow, UK; Cancer Research UK Beatson Institute of Cancer Research, Glasgow, UK; Cancer Research UK Scotland Centre, Glasgow and Edinburgh, UK., Kelly C; Cancer Research UK Glasgow Clinical Trials Unit, University of Glasgow, Glasgow, UK., Tomlinson I; Department of Oncology, University of Oxford, Oxford, UK., Kerr R; Department of Oncology, University of Oxford, Oxford, UK., Kerr D; Nuffield Division of Clinical and Laboratory Sciences, University of Oxford, Oxford, UK., Domingo E; Department of Oncology, University of Oxford, Oxford, UK; Cancer Research UK Scotland Centre, Glasgow and Edinburgh, UK., Church DN; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Oxford NIHR Comprehensive Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Electronic address: david.church@well.ox.ac.uk., Koelzer VH; Department of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; Nuffield Department of Medicine, University of Oxford, Oxford, UK; Department of Oncology, University of Oxford, Oxford, UK.
Corporate Authors: TransSCOT consortium
Source: The Lancet. Oncology [Lancet Oncol] 2024 Feb; Vol. 25 (2), pp. 198-211.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-5488
DOI:10.1016/S1470-2045(23)00560-0